登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Integrin alpha D beta 2】

Integrin alpha D beta 2信息

英文名称:Integrin alpha-4
中文名称:整合素-4
靶点别称:CD49D,Integrin alpha-IV,ITGA4,Integrin Subunit Alpha 4,Alpha 4 Subunit Of VLA-4 Receptor,VLA-4 Subunit Alpha,Integrin, Alpha 4 (Antigen CD49D, Alpha 4 Subunit Of VLA-4 Receptor),CD49 antigen-like family member D,Very Late Activation Protein 4 Receptor, Alpha 4 Subunit,Antigen CD49D, Alpha-4 Subunit Of VLA-4 Receptor,Integrin Alpha-4,269C Wild Type,CD49d Antigen,Antigen CD49D,IA4,Integrin alpha4
上市药物数量:1
临床药物数量:3
最高研发阶段:批准上市

Integrin alpha D beta 2产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
IT2-H53W6
Human
Human Integrin alpha D beta 2 (ITGAD&ITGB2) Heterodimer Protein, His Tag&Tag Free
ACRO质量管理体系
 
评论(0)
 

Integrin alpha D beta 2 分子别名

Integrin alpha D beta 2,ITGAD & ITGB2

Integrin alpha D beta 2 分子背景

Integrin alpha-D/beta-2 is a receptor for ICAM3 and VCAM1. May play a role in the atherosclerotic process such as clearing lipoproteins from plaques and in phagocytosis of blood-borne pathogens, particulate matter, and senescent erythrocytes from the blood. Contributes to natural killer cell cytotoxicity. Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils. Triggers neutrophil transmigration during lung injury through PTK2B/PYK2-mediated activation (PubMed:18587400). Alpha D beta 2, selectively binds ICAM-3 and does not appear to bind ICAM-1. In addition, a soluble form of alpha D beta 2 binds VCAM-1 with greater efficiency relative to ICAM-3. The I domain of alpha D contains a binding site for VCAM-1 since recombinant alpha D I domain binds specifically to VCAM-1.

Integrin alpha D beta 2 前沿进展

Integrin alpha D beta 2上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Natalizumab biosimilar(Polpharma Biologics) PB-006; DST-356A1 批准上市 Polpharma Biologics Sa Tyruko United States 克罗恩病, 多发性硬化 Sandoz Inc 2023-08-24 复发-缓解型多发性硬化, 多发性硬化, 克罗恩病 详情

Integrin alpha D beta 2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
BIIB-107(Biogen) BIIB-107 临床一期 百健 多发性硬化 详情
ATL-1102 ATL-1102; TV-1102; ATL/TV-1102; ISIS-107248 临床二期 Ionis Pharmaceuticals Inc 多发性硬化, 杜氏肌营养不良症 详情
ELND-004 ELND-004 临床一期 Perrigo Company Plc 自身免疫疾病 详情

消息提示

请输入您的联系方式,再点击提交!

确定